Y-mAbs Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2015-04-01
- Employees
- 100
- Market Cap
- $676.1M
- Website
- http://www.ymabs.com
- Introduction
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Non-hodgkin Lymphoma
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT05994157
- Locations
- ๐บ๐ธ
HonorHealth, Scottsdale, Arizona, United States
๐บ๐ธCity of Hope, Duarte, California, United States
๐บ๐ธCorewell Health-BAMF Health, Grand Rapids, Michigan, United States
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
- Conditions
- SCLCMalignant MelanomaSarcomaHigh Risk Neuroblastoma
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT05130255
- Locations
- ๐บ๐ธ
HonorHealth, Scottsdale, Arizona, United States
๐บ๐ธCity of Hope National Medical Center, Duarte, California, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- AML, Childhood
- Interventions
- Drug: CD33*CD3 BsAb
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT05077423
- Locations
- ๐บ๐ธ
Children's of Alabama/University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธChildren's Hospital of Orange County, Orange, California, United States
๐บ๐ธUCSF Benioff Children's Hospital, San Francisco, California, United States
131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma
- Conditions
- DIPG
- Interventions
- Device: Convention Enhanced Delivery
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Y-mAbs Therapeutics
- Registration Number
- NCT05063357
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Y-mAbs Therapeutics
- Registration Number
- NCT04909515
- Locations
- ๐ญ๐ฐ
Hong Kong Children's Hospital, Kowloon, Hong Kong
๐ฐ๐ทAsan Medical Center Childrens Hospital, Seoul, Korea, Republic of
๐ฐ๐ทSamsung Medical Center, Seoul, Korea, Republic of
Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT04750239
- Locations
- ๐บ๐ธ
Moffitt Cancer Center, Tampa, Florida, United States
๐บ๐ธEmory University, Atlanta, Georgia, United States
๐บ๐ธHenry Ford Hospital, Detroit, Michigan, United States
Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma
- Conditions
- Neuroblastoma Recurrent
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT04560166
- Locations
- ๐ญ๐ฐ
Hong Kong Children's Hospital, Hong Kong, Hong Kong
๐ฐ๐ทAsan Medical Center Children's Hospital, Seoul, Korea, Republic of
๐ฐ๐ทSeoul National University Hospital, Seoul, Korea, Republic of
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
- Conditions
- Solid Tumor, AdultLeptomeningeal Metastasis
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Y-mAbs Therapeutics
- Registration Number
- NCT04315246
- Locations
- ๐บ๐ธ
Cedars-Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธJohns Hopkins, Baltimore, Maryland, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT04167618
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธDoernbecher Children's Hospital, Portland, Oregon, United States
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
- Conditions
- OsteosarcomaNeuroblastomaOther Solid Tumor Cancers
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Y-mAbs Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT03860207
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States